linjc16/ctgov huggingface dataset:
Association Between Hepatitis C Infection and Renal Cell Carcinoma

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if there is an association between hepatitis C infection and kidney cancer. All patients who are diagnosed with kidney cancer and who will either have a biopsy or surgery will be offered to be tested for hepatitis C. The control group will be colon cancer patients. Both groups would be of recent diagnosis (6 months).

Official Title
-----------------
Association Between Hepatitis C Infection and Renal Cell Carcinoma, a Case Control Study

Conditions
-----------------
Hepatitis C, Renal Cell Carcinoma, Colorectal Cancer

Intervention / Treatment
-----------------
* Other: Hepatitis C testing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and female patients 18 years or older in whom renal cell carcinoma is suspected and are scheduled for either biopsy or partial or total nephrectomy. Diagnosis within 6 months. Male and female patients 18 years or older in whom colorectal cancer has been diagnosed within the last 6 months Exclusion Criteria: Patients who are unwilling to provide consent Patients who decline to complete a questionnaire Patient in who blood sample cannot be obtained Diagnosis of renal cell carcinoma or colon cancer greater than 6 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Renal Cell Carcinoma patients<br>Newly diagnosed (within 6 months) renal cell carcinoma patients in who a biopsy or surgery will be performed | Other: Hepatitis C testing<br>* Hepatitis C antibody, Hepatitis C RNA quantitative and for those who test positive Hepatitis C genotype<br>|
| Colorectal cancer patients<br>Newly diagnosed (6 months) colon cancer patients | Other: Hepatitis C testing<br>* Hepatitis C antibody, Hepatitis C RNA quantitative and for those who test positive Hepatitis C genotype<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of hepatitis C in renal cell carcinoma patients | Determine the prevalence of hepatitis C infection in newly diagnosed renal cell carcinoma patients | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hepatitis C, Renal Cell Carcinoma, Colorectal Cancer
Evaluate Clinical and Radiological Outcomes After Limb Reconstruction Using Monorail Fixator Over Intramedullary Nailing in Tibial Open Fractures With Bone Loss

Study Overview
=================
Brief Summary
-----------------
Road traffic accidents (RTA) is the most common cause of open fractures of long bones, increase in RTA leading to increase of complex non-unions incidence. the Participants are usually undergoing multiple surgeries for healing or to eradicate infection, which in turn leading to loss of bone and soft tissues and require skin grafting, muscle pedicle graft or bone grafting. Sometimes the Participants end up with deformity, limb length discrepancy, joints stiffness, disuse osteoporosis and muscle atrophy after management

Official Title
-----------------
Management of Open Tibial Fractures With Bone Loss Using Monorail Fixator Over Intramedullary Nail

Conditions
-----------------
Open Fracture Tibia

Intervention / Treatment
-----------------
* Procedure: intramedullary nail with Limb Reconstruction System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age from 18-60 years old. Open Grade II, Open Grade III (a & b) diaphyseal fractures of Tibia (judged after primary and/or secondary to debridement). Bone defect < 10 cm. Patients with Injury severity score (ISS) < 17. Exclusion Criteria: Massive bone defect > 10 cm. Patients with ISS > 17, polytrauma patient. Age < 18 years old or > 60 years old. Associated vascular injury ischemic limb.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Participants<br>patients undergoes intramedullary nail with Limb Reconstruction System | Procedure: intramedullary nail with Limb Reconstruction System<br>* bone transport by Limb Reconstruction System over intramedullary nail on fracture tibia<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ASAMI Scoring System | excellent : active , no limping good : active with one or more of : limp , stiffness , significant pain Fair : active with at least three of the following : limping , stiffness , significant pain , reflex sympathetic syndrome Poor : Inactive Failures : Amputations | 1 year |
Cell Selection for Bone Marrow Transplants to Prevent Graft-Versus-Host-Disease

Study Overview
=================
Brief Summary
-----------------
Blood contains different kinds of cells, white blood cells, red blood cells, and platelets. In order to treat certain diseases, specific cell types can be removed from blood and transplanted into patients. The process of removing white blood cells for the treatment of leukemia is called apheresis. This study will make available blood cell collections from volunteers genetically matched to various degrees with recipients in order to test and, if necessary, refine the process of removing white blood cell T-lymphocytes....

Detailed Description
-----------------
This protocol has been written to make available apheresis collections from volunteers matched to various degrees with recipients in order to test and, if necessary refine, the selective immunodepletion procedure prior to introducing it in a clinical trial.

Official Title
-----------------
Apheresis of Family Members of Patients Undergoing Allogeneic Bone Marrow Transplantation. A Pre-Clinical Study of Selective Depletion of Donor Lymphocytes to Prevent Acute Graft-Versus-Host Disease

Conditions
-----------------
Graft vs Host Disease, Hematologic Neoplasm

Participation Criteria
=================
Eligibility Criteria
-----------------
INCLUSION CRITERIA: Family members of patients admitted to NHLBI allogeneic BMT protocols. Ages 18 and older and less than age 65. Parent of patient (obligate haplotype match) OR HLA 3/6, 4/6, 5/6, or 6/6 match with patient. Research apheresis available from patient. EXCLUSION CRITERIA: Pregnancy or lactation. HLA type unknown. More than one haplotype mismatch with patient. History of any immunosuppressive disease. History of chronic viral antigenic stimulus. Venous access inadequate.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Volunteer, Leukocyte Donors, Family Members, Leukocyte Collection, No Reimbursement
Passive Prophylaxis of Lyme Disease Using Permethrin Treated Clothes

Study Overview
=================
Brief Summary
-----------------
Hypothesis: Does treatment of lower extremity clothing with permethrin prevent Lyme disease? This is a double-blind, randomized clinical trial using permethrin treatment of clothing to prevent Lyme disease.

Detailed Description
-----------------
This is a double-blind, randomized clinical trial using permethrin treatment of clothing to prevent Lyme disease. Subjects (N=200) will be recruited from camp staff to participate in the study and screened by inclusion and exclusion criteria.Qualifying subjects will be randomized to either the treatment (N=100) or non-treatment arm (N=100). Subjects in the treatment arm will have their scout shorts, pants, and socks sprayed with 0.5% permethrin and allowed to dry. Subjects in the non-treatment arm will have their scout shorts, pants, and socks sprayed with water and allowed to dry. Subjects will then be followed over the summer camping season to see if they develop Lyme disease. At 70 days, all subjects will have their Lyme titers rechecked to ensure that all cases of Lyme disease were documented. Following the 70 day visit, there will be an assessment of the final study outcomes.

Official Title
-----------------
Passive Prophylaxis of Lyme Disease Using Permethrin Treated Clothes

Conditions
-----------------
Lyme Disease

Intervention / Treatment
-----------------
* Other: Permethrin
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Summer camp staff at Tomahawk Scout Reservation Works in an outdoor environment Sleeps in an outdoor environment (platform tent) Present for the entire camp season (June - August) Informed consent Exclusion Criteria: Contraindication, allergy or previous reaction to permethrin Inability of subject or surrogate (e.g., parent if < 18 years of age) to provide informed consent

Ages Eligible for Study
-----------------
Minimum Age: 14 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Permethrin treatment of clothing<br>0.5% permethrin sprayed one time on uniform shorts, pants, and socks | Other: Permethrin<br>* Permethrin 0.5% treatment of clothing one time<br>|
| Sham Comparator: Placebo<br>Water sprayed on uniform shorts, pants, and socks | Other: Placebo<br>* water sprayed on clothing one time<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of Lyme disease |  | Day <=70 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Lyme disease, tick
Effects of a Smoking Cessation Program for Prison Inmates

Study Overview
=================
Brief Summary
-----------------
According to WHO database, an average of 540 million people worldwide dies from smoking related diseases every year. The use of tobacco products may reduce the average life expectancy of about 15 years. The data of 2009 from Department of Health Bureau of Health showed 38.57% male adults and 4.75% female adults smoked in Taiwan. Studies about smoking rate within prison inmates were between 64-91.8%, which was over 3 times than the general population. Smoking cessation can lower the risks of smoking related health problems. Two thirds of smokers in Taiwan once tried smoking cessation but the success rate was about 5% every year. In view of high smoking rate within prison inmates in Taiwan, Agency of Correction, Ministry of Justice announced a smoking cessation program for inmates in April 2010. The purpose of this study was to investigate the effects of this program and the difference of cessation success rate between various interventional methods, using questionnaires for smokers and smoking cessation clinics database.

Official Title
-----------------
Effects of a Smoking Cessation Program for Prison Inmates-A Case Study of a Prison in Central Taiwan

Conditions
-----------------
Smoking Cessation

Intervention / Treatment
-----------------
* Behavioral: Smoking Cessation Program


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Prison inmates with age equal or more than 20 years old and have smoked for equal or more than one year

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Non-Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Smoking Cessation Program<br> | Behavioral: Smoking Cessation Program<br>* Comparison of smoking cessation rate among different smoking cessation program<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Smoking Cessation Rate |  | 6 months after each subject's enrollment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Smoking cessation rate
Registry of Malignant Arrhythmias and Sudden Cardiac Death - Influence of Diagnostics and Interventions

Study Overview
=================
Brief Summary
-----------------
The Registry of Malignant Arrhythmias and Sudden Cardiac Death - Influence of Diagnostics and Interventions (RACE-IT) represents a mono-centric registry of patients being hospitalized suffering from malignant arrythmias (ventricular tachycardia or fibrillation) and sudden cardiac death (SCD). Detailed findings of patients' clinical outcome regarding mortality and co-morbidities related to the presence of invasive diagnostics or therapies including coronary angiography, percutaneous coronary intervention (PCI), electrophysiological testing (EP), catheter ablation and implanted cardiac devices (e.g. implantable cardioverter-defibrillators) will be documented. Patients will be included when being hospitalized from the year 2004 until today.

Official Title
-----------------
Registry of Malignant Arrhythmias and Sudden Cardiac Death - Influence of Diagnostics and Interventions

Conditions
-----------------
Ventricular Tachycardia, Ventricular Fibrillation, Sudden Cardiac Death, Coronary Angiography, Electrophysiologic Testing (EP), Catheter Ablation, Percutaneous Coronary Intervention (PCI), Internal Cardioverter Defibrillator (ICD)

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hospitalization due to: ventricular tachycardia ventricular fibrillation sudden cardiac death Exclusion Criteria: not diagnosed with one or more of the above

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of ventricular arrythmias (i.e. ventricular fibrillation, ventricular tachykardia, asystole, SCD) |  | Through study completion, potentially up to 12 years, depending on patient inclusion/first event and patients lifetime | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of coronary artery disease (CAD) and PCI in patients with VF/VT/SCD |  | Through study completion, potentially up to 12 years, depending on patient inclusion/first event and patients lifetime | 
| Incidence of invasive electrophysiologic testing (EP) and catheter ablation |  | Through study completion, potentially up to 12 years, depending on patient inclusion/first event and patients lifetime | 
| Incidence of treatment with cardiac devices (i.e. ICD, CCM, CRT-D) |  | Through study completion, potentially up to 12 years, depending on patient inclusion/first event and patients lifetime | 
| Incidences of recurrent malignant tachycardias, all-cause mortality, arrhythmia-related death, re-PCI/ACVB, re-ablation, further therapy with cardiac devices |  | Through study completion, potentially up to 12 years, depending on patient inclusion/first event and patients lifetime |
Duchenne Muscular Dystrophy Tissue Bank for Exon Skipping

Study Overview
=================
Brief Summary
-----------------
We will utilize the Cooperative International Neuromuscular Research Group (CINRG) network to collect and store tissue and blood from patients with Duchenne muscular dystrophy (DMD) with specific genetic mutations within the dystrophin gene that could be treated by antisense oligonucleotide (AO) drugs.

Detailed Description
-----------------
The purpose of this tissue bank is to collect blood and skin samples from participants who are diagnosed with Duchenne muscular dystrophy (DMD) and carry one of nine specific changes in the dystrophin gene. The specific dystrophin changes that we are interested in studying are those that would work with exon-skipping therapies in patients with DMD, specifically deletions of the follow exons: 10-52, 13-50, 29-50, 43-52, 44, 43-50, 45-50, 45-52, 46, 46-47, 46-48, 46-49, 46-51, 46-53, 46-55, 46-60, 47-50, 47-52, 48-50, 49-50, 50, 52, 52-63, 48-52, 49-52, 50-52. These blood and skin samples will be held in a tissue bank at Carolinas Medical Center for future DMD research.

Conditions
-----------------
Duchenne Muscular Dystrophy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 4 and above Diagnosis of DMD with a confirmed out-of-frame dystrophin gene deletions that could be corrected by skipping exon 45, 51, or 53 based on past genetic testing. Exclusion Criteria: Investigator assessment of inability to comply with blood and skin sample collection

Ages Eligible for Study
-----------------
Minimum Age: 4 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Duchenne muscular dystrophy<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tissue Collection | Collection of blood, skin and optional muscle samples | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
muscular dystrophy, tissue bank
Therapeutic Effect of New Biologics in Crohn's Disease

Study Overview
=================
Brief Summary
-----------------
New types of biologics have brought advantages in therapy strategies for Crohn's disease. However, clinical data evaluating their efficacy and adverse in China is lacking. We aimed to evaluate the short-term and long-term therapeutic effect as well as drug adverse of Ustekinumab (UST) and Vedolizumab (VED). Besides, we aim to figure out the independent factors predicting the effectiveness of new biologics. Relations between drug exposure (trough concentration and antibody concentration) and therapeutic efficacy are study in-depth by this retrospective observational study.

Official Title
-----------------
Therapeutic Effect of New Biologics in Crohn's Disease

Conditions
-----------------
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Treatment Side Effects

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Consecutive adult patients with confirmed diagnosis of Crohn's disease and administration of new type biologics. Exclusion Criteria: loss of follow-up, incomplete clinical data, without confirmed diagnosis

Ages Eligible for Study
-----------------
Minimum Age: 17 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| endoscopic remission | Endoscopic remission referred to those with simple endoscopic score for Crohn's disease (SES-CD)≤2 | short-time efficacy (16-20 weeks or 24 weeks) and long-term efficacy (52 54weeks) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| clinical remission | Clinical remission was defined as Crohn's disease activity index (CDAI) below 150 | short-time efficacy (16-20 weeks or 24 weeks) and long-term efficacy (52 54weeks) | 
| clinical response | endoscopic response referred to those with a reduction of SES-CD > 50% baseline | short-time efficacy (16-20 weeks or 24 weeks) and long-term efficacy (52 54weeks) | 
| endoscopic response | endoscopic response referred to those with a reduction of SES-CD > 50% baseline | short-time efficacy (16-20 weeks or 24 weeks) and long-term efficacy (52 54weeks) |
Duration of Use of Highly Effective Reversible Contraception

Study Overview
=================
Brief Summary
-----------------
To assess the proportion of women who use HERC for ≥2 years of duration

Official Title
-----------------
Real-world Duration of Use for Highly Effective Reversible Contraception (HERC): A Retrospective Review

Conditions
-----------------
Pregnancy

Intervention / Treatment
-----------------
* Drug: Mirena (Levonorgestrel IUS, BAY86-5028)
* Drug: ParaGard
* Drug: Implanon/Nexplanon


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: -Women who had an IUD or contraceptive implant inserted and removed within the University of Utah from January 1, 2004 to October 31, 2012

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 44 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| HERC<br>Women who had an insertion of HERC (Mirena IUD, ParaGard IUD, Implanon or Nexplanon) | Drug: Mirena (Levonorgestrel IUS, BAY86-5028)<br>* Levonorgestrel-releasing intrauterine device 20 mcg/day<br>Drug: ParaGard<br>* Copper T380A<br>Drug: Implanon/Nexplanon<br>* Etonorgestrel contraceptive implant<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of women who use HERC |  | 2 years post-HERC initiation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Duration of real world use of three different HERC devices |  | 2 years post-HERC initiation |